Table 2.

Efficacy at week 4

Outcome	Mean ± SD
	Placebo (n=51)	Fasinumab
		0.1 mg/kg (n=53)	0.3 mg/kg (n=53)
AUC of average leg pain (baseline to week 4)
All patients	96.8±56.0	112.7±58.3a	112.4±55.8b
Patients with pain duration 2–8 weeks	95.3±56.3	114.9±60.5	111.9±54.7
Patients with pain duration >8–16 weeks	99.3±57.0	107.6±54.3	113.6±60.6
Change in average leg pain NRS	−3.0±2.5	−2.3±2.2	−2.9±2.4
Change in worst leg pain NRS	−3.7±2.9	−3.2±2.5	−3.7±2.8
Change in average back pain NRS	−2.6±2.3	−2.1±2.3	−2.8±2.2
Change in worst back pain NRS	−3.1±2.8	−3.1±2.7	−3.6±2.5
Change in ODI	−0.1±0.2	−0.1±0.1	−0.2±0.1
PGIC score	3.0±1.1	2.8±1.2	2.6±1.0

Notes:

^aP=0.0610 and

^bP=0.0923 using an analysis of covariance model with treatment and duration of pain as fixed factors and baseline pain score as a covariate.

Abbreviations: AUC, area under the curve; NRS, numerical rating scale; ODI, Oswestry Disability Index; PGIC, Patient Global Impression of Change; SD, standard deviation.